Table 2.

Paclitaxel-treated patients using P-gp inhibitors have a higher risk of dose modification due to peripheral neuropathy.

P-gp inhibitorsa	n	Univariate analysis	Multivariate analysisb
		Odds-ratio (95% confidence interval)	Odds-ratio (95% confidence interval)
Any inhibitor	117	2.55 (1.51–4.31)	2.36 (1.31–4.25)
Strong inhibitor	24	5.73 (2.46–13.36)	4.73 (1.88–11.90)
Atorvastatin	16	9.41 (3.30–26.82)	7.01 (2.28–21.53)
Simvastatin	26	0.63 (0.18–2.16)	0.33 (0.09–1.19)

^aDrugs listed as P-gp inhibitors by Lund et al. [31] or Wessler et al. [32].

^bAdjusted for age, body surface area, tumor type, cancer stage, treatment schedule and previous chemotherapy.